2 Manitoba regional health authority leaders sacked as province releases financial audits
Probes into spending by Manitoba's regional health authorities over the last few years have found "systemic government failures," the province's health minister said as two new leaders were announced.
The audits, done by consulting firm Deloitte for fiscal years from 2019-20 to 2023-24, discovered a "disconnect" between the province's order to improve health-care culture and decisions made by system leaders, Uzoma Asagwara said in a news release Wednesday.
All of Manitoba's regional health authorities were examined, except for Southern Health-Santé Sud, after the province commissioned the audits in March 2024, the release said. All but one of the health authorities reported year-after-year deficits in the audits.
The accumulated deficits are the result of a culture in Manitoba's health-care system that fails to distribute funds to the front lines, deprioritizes patients and ignores front-line health-care workers, Asagwara said.
Temporary leaders for two of the health authorities that underwent the audits were also announced on Wednesday.
Chris Christadoulou has been named interim CEO of Shared Health, the organization said in a news release. He's replacing Lanette Siragusa, who served as head of the health authority since April 2023 after becoming a familiar face in Manitoba during the COVID-19 pandemic.
Jane Curtis, who previously led Southern Health-Santé Sud, has been named interim CEO of the Winnipeg Regional Health Authority, a news release said. She's replacing Mike Nader, who had been in the role since April 2021.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
14 hours ago
- Toronto Star
Alberta premier defends charging most Albertans for COVID-19 vaccines
EDMONTON - Alberta Premier Danielle Smith says her government's new policy forcing many Albertans to pay out of pocket for a COVID-19 vaccination is about focusing on those who need it the most. Smith says $135 million got 'flushed down the drain' last year from doses wasted in part because of low vaccine uptake. Her government will still pay for some, including for those who have compromised immune systems or are on social programs, to get shots. ARTICLE CONTINUES BELOW Smith says she thinks low vaccination rates for COVID-19 in Alberta last year are because the vaccine 'doesn't work particularly well.' The Opposition NDP says it's a cruel move to charge Albertans who want to protect their health and their loved ones. Public health-care experts say fewer people will get vaccinated and it could lead to higher costs for things like hospital stays. This report by The Canadian Press was first published June 14, 2025.
Winnipeg Free Press
14 hours ago
- Winnipeg Free Press
Alberta premier defends charging most Albertans for COVID-19 vaccines
EDMONTON – Alberta Premier Danielle Smith says her government's new policy forcing many Albertans to pay out of pocket for a COVID-19 vaccination is about focusing on those who need it the most. Smith says $135 million got 'flushed down the drain' last year from doses wasted in part because of low vaccine uptake. Her government will still pay for some, including for those who have compromised immune systems or are on social programs, to get shots. Smith says she thinks low vaccination rates for COVID-19 in Alberta last year are because the vaccine 'doesn't work particularly well.' The Opposition NDP says it's a cruel move to charge Albertans who want to protect their health and their loved ones. Public health-care experts say fewer people will get vaccinated and it could lead to higher costs for things like hospital stays. This report by The Canadian Press was first published June 14, 2025.
Montreal Gazette
18 hours ago
- Montreal Gazette
Opinion: U.S. vaccine funding cancellation is disastrous
With Donald Trump's second administration, disruptive news seems to arise on a daily basis. Most concerning for clinicians and health scientists in Canada and around the world was Trump's appointment of anti-vaccination advocate Robert F. Kennedy Jr. to the enormously influential position of secretary of health and human services. Kennedy's ideological dismantling of the U.S.'s vaunted health research apparatus has been at a speed that's surprising even to his most ardent critics. But his recent decision to cancel a nearly US$600-million contract with vaccine manufacturer Moderna may be among his most short-sighted and destructive moves, with ripple effects globally. The contract with the mRNA pioneer, signed under the Joe Biden administration, was meant to fund the development, testing and licensing of vaccines targeting particular flu strains, including the strain responsible for the dreaded avian flu, H5N1. Many scientists fear H5N1 could become the next world-stopping infectious disease pandemic. The main reason cited for the cancellation was concern for the safety and testing of mRNA vaccine technology. But the company's mRNA COVID vaccines are among the most tested and scrutinized medical products in human history. The withdrawal of the U.S. from efforts to produce an mRNA vaccine against H5N1 is indeed troubling. When it infects humans, H5N1 kills about 50 per cent of the time. Canada's only known domestically acquired human case of H5N1 to date was discovered in November. The current outbreak among dairy herds in the U.S. has spread to at least 17 states and more than 1,000 herds. The increasing number of domestic and wild animals found to be infected is worrying, suggesting that the dreaded mutation allowing easy human-to-human transmission is becoming more likely by the day. When that happens, many people will die, and many more will clamour for a vaccine. Luckily, we already have more than one licensed H5N1 vaccine based on older, non-mRNA technology. But their efficacy is largely unknown, and many of them are manufactured via incubating the virus inside live eggs. In the event of an avian flu pandemic, finding enough uninfected eggs to produce doses at scale could be problematic. More challenging is the lead time for manufacturing these traditional vaccines. At the very least, many months are needed, which is why the seasonal flu vaccine is often a poor match to circulating strains, resulting in middling efficacy. If an H5N1 pandemic is in our near future, it will not be possible to manufacture sufficient doses of the currently licensed vaccines quickly enough to protect everyone. The only proven vaccine technology capable of the kind of rapid production needed to quell a sudden pandemic is the mRNA platform. Five years of refinement over the course of the COVID era has afforded Moderna and Pfizer a kind of confident fluency in their development and deployment acumen. Other companies have since adopted the technology as well. Another consideration is viral mutation. If H5N1 makes the mutational leap to sustained human-to-human transmission, it will be because its genetic makeup will have changed enough to make that happen. In other words, the virus will be measurably different from that used to create the currently licensed formulations. The mRNA platform will be needed to quickly pivot to targeting the new viral formulation. It can do so with much more adeptness and fluidity than the lumbering egg- and cell-incubated vaccines currently stockpiled. Remember: the first COVID mRNA vaccine was finalized just 48 hours after scientists sequenced the genetic code of the virus that causes COVID. RFK Jr.'s decision to cancel this funding is short-sighted and seemingly driven by skewed and nonsensical anti-vax perceptions. It comes at a time when early clinical trials had already demonstrated the safety of Moderna's investigational pandemic influenza vaccine, called mRNA-1018. Perhaps this is an opportunity for other countries — such as Canada — to fill the funding void and claim the financial and societal benefits of this transformational technology.
